GT-02287, an oral Parkinson’s disease therapy from Gain Therapeutics, showed promising results in a Phase 1b trial. Over three months of treatment, patients had lower levels of DOPA decarboxylase (DDC) in their cerebrospinal fluid — a biomarker linked to Parkinson’s activity. Motor function remained stable over five months of treatment.
